Guggenheim raised the firm’s price target on Regeneron (REGN) to $865 from $815 and keeps a Buy rating on the shares following Q3 performance that was driven by strong Dupixent sales. Upcoming potential catalysts include full data from cemdisiran in generalized myasthenia gravis, the upcoming PDFUAs for Eylea HD label expansions, and LAG-3 data in melanoma in the first half of 2026, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $627 from $543 at BofA
- Cautious Outlook on Regeneron Amid Eylea Erosion and Medicare Policy Risks
- Regeneron Pharmaceuticals Faces Financial Risks Amid Tariff and Trade Challenges
- Regeneron Pharmaceuticals Reports Q3 2025 Financial Results
- Regeneron Earnings Call: Strong Growth Amid Challenges